Page last updated: 2024-09-03

mk 0663 and abt 102

mk 0663 has been researched along with abt 102 in 1 studies

Compound Research Comparison

Studies
(mk 0663)
Trials
(mk 0663)
Recent Studies (post-2010)
(mk 0663)
Studies
(abt 102)
Trials
(abt 102)
Recent Studies (post-2010) (abt 102)
54917326523317

Protein Interaction Comparison

ProteinTaxonomymk 0663 (IC50)abt 102 (IC50)
Cytochrome P450 3A4Homo sapiens (human)0.004
Transient receptor potential cation channel subfamily V member 1Homo sapiens (human)0.0031

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Best, AE; Duan, WR; Faltynek, CR; Locke, C; Nothaft, W; Othman, AA; Reeh, P; Schaffler, K1

Trials

1 trial(s) available for mk 0663 and abt 102

ArticleYear
An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin.
    British journal of clinical pharmacology, 2013, Volume: 75, Issue:2

    Topics: Administration, Oral; Adult; Analgesics, Opioid; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Etoricoxib; Evoked Potentials; Hot Temperature; Humans; Indazoles; Lasers, Gas; Male; Pain; Pain Measurement; Pyridines; Severity of Illness Index; Skin; Sulfones; Tramadol; TRPV Cation Channels; Ultraviolet Rays; Urea

2013